09 / 25 / 2019
VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada
Media Room
07 / 25/ 2019
AbbVie is committed to the elimination of hepatitis C in Canada by 2030
Learn more
Learn more
People. Passion. Possibilities.
AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives.
Innovation that makes a difference.
We're tackling diseases where there is a significant need for more and better solutions.
Our medicines have impact all over the world. So could you.
We are always looking for talented people to join our team.
Leave AbbVie.ca
You are now leaving the AbbVie.ca Web site. The AbbVie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in Canada.
Do you wish to continue?
Exit AbbVie.ca
Notice
You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation. This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
Do you wish to leave this site?
